Hsa_Circrna_103636: Potential Novel Diagnostic and Therapeutic Biomarker in Major Depressive Disorder

Xuelian Cui(Nanjing Medical University), Wei Niu(Chinese People 's Liberation Army No. 85 Hospital), Lingming Kong(Fourth People's Hospital of Changzhou), Mingjun He(Soochow University), Kunhong Jiang(Fourth People's Hospital of Changzhou), Shengdong Chen(Chinese People 's Liberation Army No. 85 Hospital), Aifang Zhong(Chinese People 's Liberation Army No.455 Hospital), Wanshuai Li(Changzhou No.2 People's Hospital), Jim Lu(SignPath Pharma (United States)), Li-Yi Zhang(Fourth People's Hospital of Changzhou)
Biomarkers in Medicine
July 12, 2016
Cited by 162

Abstract

AIM: This study aimed to determine whether circular RNA (circRNA) molecules in peripheral blood mononuclear cells (PBMCs) could be used as novel non-invasive biomarkers for major depressive disorder (MDD). MATERIALS & METHODS: Differentially expressed circRNAs were screened using an Arraystar Human CircRNA Array (which includes 13,617 human circRNAs) and qRT-PCR. Thirty MDD patients were randomly selected to retest the circRNA levels after 4-week and 8-week antidepressant regimens. RESULTS: Four differentially expressed circRNAs were identified between MDD patients and controls, and only down-regulated hsa_circRNA_103636 was significantly altered after the 8-week treatment in MDD patients. CONCLUSION: These results suggest that altered expression of hsa_circRNA_103636 in PBMCs is a potential novel biomarker for the diagnosis and treatment of MDD.


Related Papers

No related papers found

Powered by citation graph analysis